Rallybio Corporation Profile Avatar - Palmy Investing

Rallybio Corporation

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a…

Biotechnology
US, New Haven [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Rallybio Corporation mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of RLYB's Analysis
CIK: 1739410 CUSIP: 75120L100 ISIN: US75120L1008 LEI: - UEI: -
Secondary Listings
RLYB has no secondary listings inside our databases.